[Effect of rosiglitazone on level of serum TNF-alpha and its relation with insulin resistance in type 2 diabetes mellitus].
OBJECTIVE
To investigate the change of serum TNF-alpha level in type 2 diabetes mellitus after treating with rosiglitazone, and the relationship between TNF-alpha and insulin resistance.


METHODS
The level of serum TNF-alpha in 27 patients was tested by radioimmunoassay before and after treating with rosiglitazone. Free insulin, free blood sugar, TG, HDL-C and weight were measured, and HOMA-IR was calculated.


RESULTS
The level of serum TNF-alpha in the patients was higher than that in the controls (P < 0.005) and rosiglitazone could decrease the level of serum TNF-alpha (P < 0.001). The level of serum TNF-alpha was positively related to serum TNF-alpha, TG, FBS and ln (HOMA-IR), and it was negatively related to HDL-C (r = -0.508, P < 0.05).


CONCLUSIONS
Rosiglitazone can decrease the level of serum TNF-alpha significantly and improve insulin resistance.
Chen
Hui-Ling
HL
Department of Endocrinology, Xiangya Hospital, Central South University, Changsha 41.0008, China. cathychen20022002@yahoo.com.cn
Wu
Jing
J
Liao
Lan
L
D000328:Adult; D000368:Aged; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007333:Insulin Resistance; D008297:Male; D008875:Middle Aged; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000627:therapeutic use*; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism*
D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D014409:Tumor Necrosis Factor-alpha; D000077154:Rosiglitazone